Liver cancer is the sixth most commonly diagnosed cancer and accounts for the fourth
leading cause of cancer-related death worldwide. 1 Hepatocellular carcinoma (HCC) is by …

Importance The recent development of targeted therapy and immunotherapy has made
neoadjuvant therapy an attractive option for patients with hepatocellular carcinoma (HCC) …

Background Drug development in hepatocellular carcinoma (HCC) is limited by disease
heterogeneity, with hepatic reserve being a major source of variation in survival outcomes …

Hepatotoxicity of chemotherapeutic agents such as methotrexate, oxaliplatin, and irinotecan
have been well documented and characterized allowing for careful management by …

A constant increase in occurrence of neoplasms is observed; hence new methods of therapy
are being intensively researched. One of the methods of antineoplastic treatment is …

Abstract Abstract 3975 Background: Bortezomib (btz, VELCADE®) is approved in the US for
the treatment of patients (pts) with multiple myeloma, and for the treatment of pts with mantle …

Hepatic impairment (HI) influences the pharmacokinetics and pharmacodynamics of drugs
and represents an important risk factor for drug safety. A reliable screening tool for HI …

ABSTRACT Background Caucasian and Asian patients (pts) with hepatocellular carcinoma
(HCC) tolerate anticancer drugs differently. This open-label, multicentre, phase I/randomised …

The treatment landscape of hepatocellular cancer has changed significantly within the past
few years. At JADPRO Live Virtual 2020, Bridget O'Brien, DNP, APRN, FNP-BC, AOCNP® …

The impact of drug-induced liver injury (DILI) is global as it is observed in all age groups and
races and across multiple continents. It is associated with a wide range of therapeutic drugs …